These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 17955841

  • 1. Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration.
    Ehlers JP, Fintak DR, Gupta OP, Regillo CD, Fineman MS, Ho AC.
    Ophthalmic Surg Lasers Imaging; 2007; 38(5):371-7. PubMed ID: 17955841
    [Abstract] [Full Text] [Related]

  • 2. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA, Hassan TS, Williams GA.
    Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
    [Abstract] [Full Text] [Related]

  • 3. Compassionate use of intravitreal pegaptanib in patients with age-related macular degeneration.
    Ricci F, Missiroli F, Cedrone C, Grossi M, Regine F.
    Semin Ophthalmol; 2010 Sep; 25(1-2):16-20. PubMed ID: 20507192
    [Abstract] [Full Text] [Related]

  • 4. Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study.
    Weber PA, Wirostko BM, Xu X, Goss TF, Zlateva G.
    BMC Ophthalmol; 2010 Feb 09; 10():2. PubMed ID: 20144224
    [Abstract] [Full Text] [Related]

  • 5. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupCentre for Vision Sciences, The Queen's University of Belfast and The Royal Victoria Hospital, Belfast, United Kingdom., Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M.
    Ophthalmology; 2006 Sep 09; 113(9):1508.e1-25. PubMed ID: 16828500
    [Abstract] [Full Text] [Related]

  • 6. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun 09; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep 09; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.
    Ophthalmology; 2008 Feb 09; 115(2):347-354.e2. PubMed ID: 17628685
    [Abstract] [Full Text] [Related]

  • 14. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 Feb 09; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

  • 15. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M, Feucht N, Huebner M, Lohmann C.
    Klin Monbl Augenheilkd; 2008 Jun 09; 225(6):582-7. PubMed ID: 18516780
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome.
    Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA.
    Retina; 2006 Jun 09; 26(6):602-12. PubMed ID: 16829800
    [Abstract] [Full Text] [Related]

  • 20. Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration.
    Emerson GG, Flaxel CJ, Lauer AK, Stout JT, Emerson MV, Nolte S, Wilson DJ, Klein ML.
    Retina; 2007 Jun 09; 27(6):724-9. PubMed ID: 17621181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.